Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

Here’s a quick biology lesson on semaglutide’s mechanisms of action (stick with us — we ... the manufacturer of the diabetes and weight loss drugs Mounjaro® and Zepbound®.

But it is an oral version of the GLP-1 analogue that holds the greatest promise for patients with diabetes - and for the company's revenues. Phase 3 trials of injectable semaglutide have shown it ...

The SOUL trial showed that oral semaglutide was safe in patients with type 2 diabetes and atherosclerotic cardiovascular ...

Scientists may have identified a way to naturally regulate blood sugar levels and sugar cravings in a similar fashion to ...

Semaglutide effectively treats liver disease in two thirds of patients, new research has found. Results from the ESSENCE phase 3 clinical trial published today in the New England Journal of Medicine ...

Semaglutide has “multiple mechanisms of action,” Rizzo says ... “Patients who take these medications already have diabetes or overweight, so they’re already at an increased risk for ...

Semaglutide use associated with increased risk for NAION at the two-, three-, and four-year time point from the index date. (HealthDay News) — For patients with diabetes, semaglutide use is ...

Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes ... from taking action against its members for making copies of semaglutide.

More information: Alan Y. Hsu et al, Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy Risk Among Patients With Diabetes, JAMA Ophthalmology (2025). DOI: 10.1001/jamaophthalmol.2025.0349 ...

Although only association and not causality can be inferred, this study showed that, among patients who had diabetes, an elevated risk of NAION was associated with semaglutide use compared with ...